HC Wainwright Reiterates Its Buy Rating For This Bioscience Company

Coherus Biosciences: A Buy Recommendation from HC Wainwright.

In a recent development, HC Wainwright reiterated its buy rating for Coherus Biosciences (NASDAQ: CHRS) and maintained a price target of $13. This announcement has sparked considerable interest among investors and market watchers, making it an urgent matter of discussion.

Founded in 2010, Coherus Biosciences is a leading biopharmaceutical company that fo…